Reactive arthritis
33,100views
00:00 / 00:00
Flashcards
Reactive arthritis
0 of 7 complete
Questions
USMLE® Step 1 style questions USMLE
0 of 2 complete
Retrieved from: Wikimedia Commons
External References
First Aid
2024
2023
2022
2021
Arthritis p. 472
reactive arthritis p. 475
Campylobacter spp.
reactive arthritis and p. 475
Chlamydia spp. p. 146
reactive arthritis p. 475
Conjunctivitis p. 549
reactive arthritis p. 475
Reactive arthritis p. 475
Campylobacter jejuni p. , 143
chlamydia p. 146, 180
HLA-B25 and p. 98
presentation p. 724
Salmonella spp.
reactive arthritis p. 475
Shigella spp.
reactive arthritis p. 475
Urethritis
reactive arthritis p. 475, 724
Yersinia spp.
reactive arthritis p. 475
Transcript
Content Reviewers
Contributors
Reactive arthritis, formerly known as Reiter’s syndrome, is inflammation of a joint which usually develops after an infection, and that infection is typically a sexually transmitted disease or gastroenteritis. Reactive arthritis is part of a group of diseases called seronegative spondyloarthropathies. Spondyloarthropathies are autoimmune, inflammatory joint diseases, and they’re seronegative, which refers to the fact that an auto-antibody called rheumatoid factor is absent from the blood.
Normally, the immune cells are ready to spot and destroy anything foreign that could cause the body harm. To help with this, most cells in the body have a set of proteins that combine together to form something called a major histocompatibility complex, or MHC, and this is a molecule that sits on the surface of their cell membrane. There are two kinds of MHC molecules, class I and class II. Class I molecules are found on most cells in the body, and they present molecules from within the cell for the immune system to continually sample. Normally the molecule’s just a sample from inside the cell, also known as a self-antigen. When immune cells pass by, they recognize this self-antigen as harmless so there’s no response.
MHC class II molecules are found specifically on phagocytic cells like macrophages which destroy and digest foreign pathogens like bacteria. Once a macrophage destroys a bacterium, it presents a piece of that bacterium on its MHC class II receptor, and the macrophage then makes its way to the lymph node to find some T-lymphocytes. A type of T-lymphocyte, called a CD4+ T-cell, also known as a helper T-cell, uses its T-cell receptors to bind to the foreign antigen presented by the MHC class II molecule. If the helper T-cell binds strongly, the antigen is recognized as foreign, and the helper T-cell switches on the corresponding B-cell, so it can start producing a whole lot of antibodies. These antibodies bind to the specific pathogen, and typically prevent it from attacking the host’s cells and, at the same time, they “tag” the pathogen for further destruction by other immune cells.
Summary
Reactive arthritis, originally referred to as Reiter's arthritis, is an autoimmune condition commonly affecting the joints, skin, and eyes, which develops in response to an infection in another part of the body. Reactive arthritis commonly presents as inflammatory arthritis of large joints, conjunctivitis or uveitis, and urethritis in men or cervicitis in women. Symptoms include joint pain and swelling, pain and swelling in the eyes, pain with urination, pain with sexual intercourse in females, and skin rashes. Treatment focuses on identifying and treating the culprit infection with antibiotics, and anti-inflammatory drugs to dampen the inflammation.
Sources
- "Robbins Basic Pathology" Elsevier (2017)
- "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
- "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
- "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
- "Poststreptococcal Arthritis" Canadian Journal of Infectious Diseases (1995)
- "Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study" Rheumatology and Therapy (2021)